HEFT Repository

Application of a Nanotechnology-Based, Point-of-Care Diagnostic Device in Diabetic Kidney Disease.

Kumar, Vinay and Hebbar, Suraj and Bhat, Ananthram and Panwar, Sachin and Vaishnav, Madhumati and Muniraj, Kavitha and Nath, Vasanthi and Vijay, Reshma Banaki and Manjunath, Sapna and Thyagaraj, Babithadevi and Siddalingappa, Chandraprabha and Chikkamoga Siddaiah, Muralidharakrishna and Dasgupta, Indranil and Anandh, Urmila and Kamala, Thummala and Srikanta, S S and Krishnaswamy, P R and Bhat, Navakanta (2018) Application of a Nanotechnology-Based, Point-of-Care Diagnostic Device in Diabetic Kidney Disease. Kidney international reports, 3 (5). pp. 1110-1118. ISSN 2468-0249. This article is available to all HEFT staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their HEFT Athens login IDs

Full text not available from this repository.
Official URL: https://www.kireports.org/article/S2468-0249(18)30...

Abstract

Introduction

Early detection of diabetes mellitus (DM) and diabetic kidney disease (DKD) is important for preventing end-stage renal failure and reducing cardiovascular complications. Availability of a validated point-of-care (PoC) device that can measure various DKD markers would be useful in this respect, especially in resource-poor parts of the world.

Methods

We validated a novel nanotechnology-based multianalyte PoC device (minimally invasive and does not require trained medical personnel) against laboratory gold standard tests for the detection of 5 biomarkers related to management of DM and DKD. The prospective study was funded by an International Society of Nephrology American Nephrologists of Indian Origin grant in 2 phases: (i) proof of concept: random samples were tested for the analytes with the PoC device and correlated with the laboratory gold standard; and (ii) clinical validation in a well-characterized cohort of patients. A nonenzymatic- and nonantibody-based electrochemical PoC device for quantitative measurement of markers-glycosylated hemoglobin (HbA), hemoglobin, serum albumin, microalbuminuria, urine creatinine, and albumin-to-creatinine ratio-was developed and used in this study. The disposable strips were interfaced with a multipotentiostat hand-held PoC device (3.7-V rechargeable lithium battery, 5-inch touch screen, Bluetooth enabled) working in amperometry mode, which provided the results in <1 minute. Data were analyzed using linearity plots and Bland-Altman difference plot analysis.

Results

A total of 4717 individuals were screened during the study (phase 1: 2576 and phase 2: 2141.) In phase 2, samples were tested in 529 subjects (346 females)-120 subjects with type 1 DM, 255 subjects with type 2 DM, 54 subjects without DM, 400 subjects with stage 2 chronic kidney disease, and 30 subjects with stage 3 chronic kidney disease.

Conclusion

A nanotechnology-based PoC device for quantitative measurement of HbA, hemoglobin, serum albumin, microalbuminuria, and the urine albumin-to-creatinine ratio was developed for detection of early DKD and showed excellent correlation between the device and laboratory results. This device has the potential for early detection of DM and/or DKD, especially in remote communities in underserved areas of the world where prevalence of diabetes is rapidly increasing.

Item Type: Article
Additional Information: This article is available to all HEFT staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their HEFT Athens login IDs
Subjects: WK Endocrine system. Endocrinology
Divisions: Emergency Services > Renal
Related URLs:
Depositing User: Mrs Yolande Brookes
Date Deposited: 14 Sep 2018 13:55
Last Modified: 14 Sep 2018 13:55
URI: http://www.repository.heartofengland.nhs.uk/id/eprint/1743

Actions (login required)

View Item View Item